Data Presented at the 2020 ADA Scientific Sessions Show that Patients Treated with Cirius Therapeutics’ MSDC-0602K Showed Improved Insulin Handling
Cirius Therapeutics Announces Results from Phase 2b NASH Study Supporting Advancing to Phase 3 Development of MSDC-0602K; Data Accepted for Late Breaker Presentation at The Liver Meeting
Cirius Therapeutics’ Phase 2b Data of MSDC-0602K for the Treatment of NASH Accepted as a Late-Breaking Oral Presentation at The Liver Meeting
Cirius Therapeutics Expands Scientific Advisory Board
Interim Data on Cirius Therapeutics’ MSDC-0602K to be Presented at the American Diabetes Association Scientific Sessions
Cirius Therapeutics Adds to Leadership Team
Cirius Therapeutics Announces Presentation of Interim Data from Phase 2b Clinical Study of MSDC-0602K at The International Liver Congress 2019
Cirius Therapeutics to Present Preclinical Data for Lead Drug Candidate in NASH at The International Liver Congress
Cirius Therapeutics Announces Two Posters on MSDC-0602K to be Presented at The Liver Meeting 2018
Cirius Therapeutics Reports Positive Data for MSDC-0602K in Interim Analysis of Phase 2b Clinical Trial in NASH Patients with Fibrosis
Cirius Therapeutics Reaches Enrollment Target in Phase 2b EMMINENCE Trial in NASH
Cirius Therapeutics’ Preclinical Data Demonstrates Potential for Lead Drug Candidate MSDC-0602K in NASH
Cirius Therapeutics to Present Late-Breaking Poster at The International Liver Congress
Cirius Therapeutics Expands Board of Directors with Appointment of Dennis M. Fenton
Cirius Therapeutics to Present Poster at The Liver Meeting 2017
Cirius Therapeutics Completes $40 Million Series A Financing to Fund Phase 2b Study of MSDC-0602K in NASH, Adds to Executive Team